Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER ‐positive breast cancer-Reference-Cited by-同舟云学术

Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER ‐positive breast cancer

Published:2020-06-18 Issue:9 Volume:147 Page:2515-2525
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Lippe Gythfeldt Hedda¹²^ORCID,Lien Tonje¹,Tekpli Xavier¹,Silwal‐Pandit Laxmi¹,Borgen Elin³,Garred Øystein³,Skjerven Helle⁴,Schlichting Ellen⁵,Lundgren Steinar⁶,Wist Erik²⁷,Naume Bjørn²⁷,Kristensen Vessela¹⁷,Børresen‐Dale Anne‐Lise¹⁷,Lingjærde Ole Christian¹⁸⁹,Engebraaten Olav²⁷

Affiliation:

1. Department of Cancer Genetics, Institute for Cancer Research Oslo University Hospital Oslo Norway

2. Department of Oncology Oslo University Hospital Oslo Norway

3. Department of Pathology Oslo University Hospital Oslo Norway

4. Department of Breast and Endocrine Surgery Drammen Hospital, Vestre Viken Hospital Trust Drammen Norway

5. Department of Breast and Endocrine Surgery Oslo University Hospital Oslo Norway

6. Department of Oncology St. Olavs University Hospital Trondheim Norway

7. Institute for Clinical Medicine University of Oslo Oslo Norway

8. Department of Informatics University of Oslo Oslo Norway

9. KG Jebsen Centre for B‐Cell Malignancies, Institute for Clinical Medicine University of Oslo Oslo Norway

Funder

Sanofi